PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3394943-2 1988 Acetylcholinesterase was carbamylated with neostigmine and diluted extensively into buffer to allow decarbamylation to occur. Neostigmine 43-54 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 34994010-4 2022 Compound 2d showed the most potent inhibitory activity among the tested molecules toward AChE and BChE (IC50 = 15.07 and 14.15 nM) compared to the standard drug neostigmine. Neostigmine 162-173 acetylcholinesterase (Cartwright blood group) Homo sapiens 89-93 34927331-4 2022 Acetylcholinesterase inhibitors, such as neostigmine and pyridostigmine, delay the degradation of acetylcholine at the synaptic cleft. Neostigmine 41-52 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 4045465-4 1985 The activity was decreased by hemicholinium-3, an inhibitor of choline uptake and slightly activated by neostigmine, an acetylcholinesterase inhibitor. Neostigmine 104-115 acetylcholinesterase (Cartwright blood group) Homo sapiens 120-140 3323058-3 1987 Monocrotophos, acothione (organophosphorus compound) and prostigmine are known inhibitors of acetylcholinesterase (AChE). Neostigmine 57-68 acetylcholinesterase (Cartwright blood group) Homo sapiens 93-113 3323058-3 1987 Monocrotophos, acothione (organophosphorus compound) and prostigmine are known inhibitors of acetylcholinesterase (AChE). Neostigmine 57-68 acetylcholinesterase (Cartwright blood group) Homo sapiens 115-119 30781917-2 1979 Three different anticholinesteratic agents (eserine, neostigmine, and diiso- propylphosphorofluoridate) at final concentrations of 10 muM caused complete inhibition of AChE activity after 30 min incubation at room temperature with either platelet-rich plasma or gel-filtered platelets. Neostigmine 53-64 acetylcholinesterase (Cartwright blood group) Homo sapiens 168-172 6275065-7 1981 When the acetylcholinesterase was inhibited with diisopropylfluorophosphate, neostigmine, or collagenase treatment to prolong the duration of the nerve-released ACh in the synaptic cleft, desensitization developed during repetitive stimulation of 1000 impulses at 5-33 impulses/sec and then recovered after the conditioning trains, with a time constant of about 25 sec.4. Neostigmine 77-88 acetylcholinesterase (Cartwright blood group) Homo sapiens 9-29 7368161-2 1980 Three different anticholinesteratic agents (eserine, neostigmine, and diisopropylphosphorofluoridate) at final concentrations of 10 muM caused complete inhibition of AChE activity after 30 min incubation at room temperature with either platelet-rich plasma or gel-filtered platelets. Neostigmine 53-64 acetylcholinesterase (Cartwright blood group) Homo sapiens 166-170 33379009-6 2021 Ki values were 4.27 mumol L-1 for neostigmine (an AChE inhibitor) and 0.40 mmol L-1 for acarbose (an alpha-glu inhibitor). Neostigmine 34-45 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-54 14099400-0 1963 [ON THE INHIBITION OF THE HISTOCHEMICAL ACETYLCHOLINESTERASE REACTION ON MOTOR END-PLATES BY INJECTIONS OF NEOSTIGMINE AND PHYSOSTIGMINE]. Neostigmine 107-118 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 13314695-0 1955 The interaction of tensilon and neostigmine with acetylcholinesterase. Neostigmine 32-43 acetylcholinesterase (Cartwright blood group) Homo sapiens 49-69 30088792-7 2019 Structural analysis revealed that neostigmine reaches the AChE binding site reported elsewhere, whereas fucosterol can act as a no-competitive and competitive acetylcholinesterase inhibitor, in agree with kinetic enzymatic experiments. Neostigmine 34-45 acetylcholinesterase (Cartwright blood group) Homo sapiens 58-62 31396774-4 2020 Pleasingly, synthesized compounds show noteworthy acetylcholinesterase (AChE) inhibitory activity with much lower IC50 values 0.0269 +- 0.0021-1.1725 +- 0.0112 muM than standard Neostigmine methylsulphate. Neostigmine 178-204 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-70 31396774-4 2020 Pleasingly, synthesized compounds show noteworthy acetylcholinesterase (AChE) inhibitory activity with much lower IC50 values 0.0269 +- 0.0021-1.1725 +- 0.0112 muM than standard Neostigmine methylsulphate. Neostigmine 178-204 acetylcholinesterase (Cartwright blood group) Homo sapiens 72-76 32761307-7 2020 Addition of the AChE inhibitors neostigmine and territrem B reduced apoptotic cell death under normal culture conditions. Neostigmine 32-43 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-20 32416089-3 2020 To restore neuromuscular transmission and skeletal muscle strength, anesthesiologists typically administer peripherally acting acetylcholinesterase inhibitors such as neostigmine. Neostigmine 167-178 acetylcholinesterase (Cartwright blood group) Homo sapiens 127-147 32416089-8 2020 Peripherally acting acetylcholinesterase inhibitors such as neostigmine should then only be administered when indicated and dosed based on results of the train-of-four ratio. Neostigmine 60-71 acetylcholinesterase (Cartwright blood group) Homo sapiens 20-40 31411109-9 2020 The use of neostigmine as a continuous subcutaneous infusion may have a role in the management of such patients, particularly when enteral administration of acetylcholinesterase inhibitors is no longer possible. Neostigmine 11-22 acetylcholinesterase (Cartwright blood group) Homo sapiens 157-177 32317886-2 2020 Even intermediate-acting NMBAs may have a prolonged effect resulting in residual weakness after reversal with acetylcholinesterase inhibitors (neostigmine). Neostigmine 143-154 acetylcholinesterase (Cartwright blood group) Homo sapiens 110-130 31650189-7 2019 Reversal by administration of the acetylcholinesterase inhibitor neostigmine reduces the incidence of residual neuromuscular block to 15.4%, in combination with calibrated acceleromyography to 3.3%. Neostigmine 65-76 acetylcholinesterase (Cartwright blood group) Homo sapiens 34-54 30373445-3 2020 Neostigmine is an acetylcholinesterase inhibitor that increases frequency of smooth muscle contraction by increasing acetylcholine at autonomic nervous system synapses. Neostigmine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 30088792-8 2019 Binding free energy calculations revealed that fucosterol reaches the acetylcholinesterase binding site with higher affinity than neostigmine, which is according to experimental results. Neostigmine 130-141 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-90 31194017-0 2019 The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications. Neostigmine 52-63 acetylcholinesterase (Cartwright blood group) Homo sapiens 12-32 24964452-1 2013 Neostigmine is an acetylcholinesterase inhibitor that is increasingly used as a medical treatment in cases of pseudo-obstruction. Neostigmine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 30478812-9 2019 Neostigmine significantly enhanced EFS responses, confirming its selectivity for inhibiting acetylcholinesterase which is responsible for termination of acetylcholine. Neostigmine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 92-112 30380560-7 2019 The acetylcholinesterase inhibitor, neostigmine (NEO; 0.5 mumol/L), also decreased transmitter exocytosis. Neostigmine 36-47 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 30380560-7 2019 The acetylcholinesterase inhibitor, neostigmine (NEO; 0.5 mumol/L), also decreased transmitter exocytosis. Neostigmine 49-52 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 30403599-1 2018 Acetylcholinesterase inhibitors, including Neostigmine, have been used to reverse neuromuscular blockage for many years. Neostigmine 43-54 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 28806470-1 2017 BACKGROUND: Acetylcholinesterase inhibitors, such as neostigmine, have traditionally been used for reversal of non-depolarizing neuromuscular blocking agents. Neostigmine 53-64 acetylcholinesterase (Cartwright blood group) Homo sapiens 12-32 28190243-7 2017 The acetylcholinesterase inhibitor neostigmine significantly increased amplitude of phasic activity only in bladder strips following castration, and this was prevented by testosterone replacement. Neostigmine 35-46 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 28894751-0 2017 Peripheral Inhibitor of AChE, Neostigmine, Prevents the Inflammatory Dependent Suppression of GnRH/LH Secretion during the Follicular Phase of the Estrous Cycle. Neostigmine 30-41 acetylcholinesterase (Cartwright blood group) Homo sapiens 24-28 28894751-6 2017 Our study shows that inflammatory dependent changes in the GnRH/LH secretion may be eliminated or reduced by AChE inhibitors suppressing inflammatory reaction only at the periphery such as Neostigmine, without the need for interfering in the central nervous system. Neostigmine 189-200 acetylcholinesterase (Cartwright blood group) Homo sapiens 109-113 32262377-7 2015 Furthermore, the presence of the acetylcholinesterase inhibitor neostigmine at concentrations as low as 1 fM was demonstrated, which is even below the necessary detection limit for clinical diagnostics. Neostigmine 64-75 acetylcholinesterase (Cartwright blood group) Homo sapiens 33-53 24215347-2 2013 In the absence of a single drug, the administration of an aminosteroid NMBA, such as rocuronium, followed by reversal using an acetylcholinesterase inhibitor, such as neostigmine, is commonly employed. Neostigmine 167-178 acetylcholinesterase (Cartwright blood group) Homo sapiens 127-147 30402044-2 2018 Neostigmine suppressed (p < 0.05) LPS-stimulated synthesis of cytokines such as interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor (TNF) alpha in the POA, and this effect was similar to that induced by the treatment with systemic AChE inhibitor-donepezil (2.5 mg/animal). Neostigmine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 240-244 29620652-7 2018 LESSONS: Our case suggests that neostigmine, an acetylcholinesterase inhibitor, may warrant further investigation in patients with thyroid storm-induced severe sinus tachycardia. Neostigmine 32-43 acetylcholinesterase (Cartwright blood group) Homo sapiens 48-68 29479387-2 2018 Agents that inhibit acetylcholinesterase, such as neostigmine, may precipitate myotonia, and are therefore relatively contraindicated. Neostigmine 50-61 acetylcholinesterase (Cartwright blood group) Homo sapiens 20-40 28169488-4 2017 Both materials were able to release rhodamine B in the presence of diisopropylfluorophosphate (DFP) or neostigmine in a concentration-dependent manner via the competitive displacement of AChE through DFP and neostigmine coordination with the AChE"s active sites. Neostigmine 103-114 acetylcholinesterase (Cartwright blood group) Homo sapiens 187-191 28169488-4 2017 Both materials were able to release rhodamine B in the presence of diisopropylfluorophosphate (DFP) or neostigmine in a concentration-dependent manner via the competitive displacement of AChE through DFP and neostigmine coordination with the AChE"s active sites. Neostigmine 103-114 acetylcholinesterase (Cartwright blood group) Homo sapiens 242-246 28169488-4 2017 Both materials were able to release rhodamine B in the presence of diisopropylfluorophosphate (DFP) or neostigmine in a concentration-dependent manner via the competitive displacement of AChE through DFP and neostigmine coordination with the AChE"s active sites. Neostigmine 208-219 acetylcholinesterase (Cartwright blood group) Homo sapiens 187-191 28169488-4 2017 Both materials were able to release rhodamine B in the presence of diisopropylfluorophosphate (DFP) or neostigmine in a concentration-dependent manner via the competitive displacement of AChE through DFP and neostigmine coordination with the AChE"s active sites. Neostigmine 208-219 acetylcholinesterase (Cartwright blood group) Homo sapiens 242-246 26799963-1 2016 INTRODUCTION: Acetylcholinesterase inhibitors (neostigmine, edrophonium) and encapsulating agents (sugammadex and calabadion) can be used to reverse residual neuromuscular blockade (NMB). Neostigmine 47-58 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-34 25519498-2 2015 Confirmation that the sensor responds to changes in extracellular choline was achieved using local perfusion of choline which resulted in an increase in current, and the acetylcholinesterase inhibitor neostigmine which produced a decrease. Neostigmine 201-212 acetylcholinesterase (Cartwright blood group) Homo sapiens 170-190 21168544-2 2011 The capability of IMS in the determination of enzyme kinetics and inhibition studies by the analysis of substrate depletion and/or product formation using only a few microliters of solution has been successfully demonstrated on the example of acetylcholine hydrolysis catalyzed by acetylcholinesterase (AChE) and inhibited by neostigmine and galanthamine. Neostigmine 326-337 acetylcholinesterase (Cartwright blood group) Homo sapiens 281-301 22750421-9 2013 Neostigmine (10 mumol l(-1)), an acetylcholinesterase inhibitor, mimicked the effects of nicotine. Neostigmine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 33-53 22037997-7 2012 Often, acetylcholinesterase inhibitors such as pyridostigmine and neostigmine are also employed to help control symptoms. Neostigmine 66-77 acetylcholinesterase (Cartwright blood group) Homo sapiens 7-27 23447584-4 2013 In humans, however, pain responses can be modulated by spinal ACh, as evidenced by the increasingly used analgesic procedure (for postoperative and labor patients) consisting of the epidural injection of the acetylcholinesterase inhibitor neostigmine. Neostigmine 239-250 acetylcholinesterase (Cartwright blood group) Homo sapiens 208-228 23476830-1 2013 Neostigmine is a parasympathomimetic drug that acts as a reversible acetylcholinesterase inhibitor. Neostigmine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 68-88 21352527-1 2011 INTRODUCTION: Neostigmine is a frequently used acetylcholinesterase inhibitor administered to reverse muscular relaxation caused by nondepolarizing neuromuscular relaxants in patients recovering from general anesthesia. Neostigmine 14-25 acetylcholinesterase (Cartwright blood group) Homo sapiens 47-67 21168544-2 2011 The capability of IMS in the determination of enzyme kinetics and inhibition studies by the analysis of substrate depletion and/or product formation using only a few microliters of solution has been successfully demonstrated on the example of acetylcholine hydrolysis catalyzed by acetylcholinesterase (AChE) and inhibited by neostigmine and galanthamine. Neostigmine 326-337 acetylcholinesterase (Cartwright blood group) Homo sapiens 303-307 20719927-8 2010 Application of the acetylcholinesterase inhibitor neostigmine significantly decreased the amplitude of glutamatergic neurotransmission to CVNs on stimulation of trigeminal fibers. Neostigmine 50-61 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-39 21034627-8 2010 Acetylcholinesterase antibody occurred more frequently in acetylcholine receptor antibody negative patients with adverse reactions to neostigmine test. Neostigmine 134-145 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 20036651-8 2010 In this model neostigmine and VX affected neuromuscular transmission as anticipated from their known actions on AChE. Neostigmine 14-25 acetylcholinesterase (Cartwright blood group) Homo sapiens 112-116 11454976-8 2001 One membrane was perfused with the acetylcholinesterase inhibitor neostigmine, while the other was perfused with the vehicle. Neostigmine 66-77 acetylcholinesterase (Cartwright blood group) Homo sapiens 35-55 20138518-1 2010 Reversible inhibitors (e.g., pyridostigmine bromide, neostigmine bromide) of carbamate origin are used in the early treatment of Myasthenia gravis (MG) to block acetylcholinesterase (AChE) native function and conserve efficient amount of acetylcholine for decreasing number of nicotinic receptors. Neostigmine 53-72 acetylcholinesterase (Cartwright blood group) Homo sapiens 161-181 20138518-1 2010 Reversible inhibitors (e.g., pyridostigmine bromide, neostigmine bromide) of carbamate origin are used in the early treatment of Myasthenia gravis (MG) to block acetylcholinesterase (AChE) native function and conserve efficient amount of acetylcholine for decreasing number of nicotinic receptors. Neostigmine 53-72 acetylcholinesterase (Cartwright blood group) Homo sapiens 183-187 21120165-2 2010 Neostigmine, an acetylcholinesterase inhibitor, has been used in patients in whom supportive therapy failed to resolve ACPO. Neostigmine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-36 17208293-5 2007 Therefore, FSM-16-TIPB was the best material, considering also that when neostigmine was applied to AChE immobilized on FSM-16-TIPB, the activity of AChE decreased as occurs in its free from. Neostigmine 73-84 acetylcholinesterase (Cartwright blood group) Homo sapiens 100-104 17208293-5 2007 Therefore, FSM-16-TIPB was the best material, considering also that when neostigmine was applied to AChE immobilized on FSM-16-TIPB, the activity of AChE decreased as occurs in its free from. Neostigmine 73-84 acetylcholinesterase (Cartwright blood group) Homo sapiens 149-153 15610710-4 2005 Acetylcholinesterase inhibitors such as pyridostigmine or neostigmine are the preferred first-line treatment for ocular myasthenia gravis, with mild cases requiring no additional intervention. Neostigmine 58-69 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 20345342-10 2010 Among data found in the literature, many compounds have shown promising inhibition of AChE when compared to commercial standards (pyridostigmine, neostigmine). Neostigmine 146-157 acetylcholinesterase (Cartwright blood group) Homo sapiens 86-90 19752726-6 2009 Acetylcholinesterase inhibitor reversal can cause respiratory side effects, so the lowest efficacious dose should be used: as little as 0.015-0.025 mg kg(-1) of neostigmine is required at a train-of-four count of four with minimal fade. Neostigmine 161-172 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 19224517-9 2009 Controlled clinical trials have shown that the acetylcholinesterase inhibitor neostigmine is an effective treatment with initial response rates of 60-90 per cent; other drugs for use in this area are in evolution. Neostigmine 78-89 acetylcholinesterase (Cartwright blood group) Homo sapiens 47-67 18242923-5 2008 This report discusses the utilization of neostigmine, an acetylcholinesterase inhibitor, for patients with colonic pseudo-obstruction. Neostigmine 41-52 acetylcholinesterase (Cartwright blood group) Homo sapiens 57-77 16579834-1 2006 Because brain extracellular acetylcholine (ACh) levels are near detection limits in microdialysis samples, an acetylcholinesterase (AChE) inhibitor such as neostigmine is often added to microdialysis perfusates to increase ACh levels in the dialysate, a practice that raises concerns that the inhibitor might alter the results. Neostigmine 156-167 acetylcholinesterase (Cartwright blood group) Homo sapiens 110-130 16579834-1 2006 Because brain extracellular acetylcholine (ACh) levels are near detection limits in microdialysis samples, an acetylcholinesterase (AChE) inhibitor such as neostigmine is often added to microdialysis perfusates to increase ACh levels in the dialysate, a practice that raises concerns that the inhibitor might alter the results. Neostigmine 156-167 acetylcholinesterase (Cartwright blood group) Homo sapiens 132-136 10826417-3 2000 Neostigmine enhances excitatory parasympathetic activity by competing with acetylcholine for attachment to acetylcholinesterase at sites of cholinergic transmission and enhancing cholinergic action. Neostigmine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 107-127 11313435-5 2001 When the solution contained 10 microM neostigmine (NEO) 3000 stimuli reduced [integral]MEPCs by 60 %, because with acetylcholinesterase (AChE) inhibited, [integral]MEPC size is more sensitive to changes in acetylcholine (ACh) content. Neostigmine 38-49 acetylcholinesterase (Cartwright blood group) Homo sapiens 115-135 11313435-5 2001 When the solution contained 10 microM neostigmine (NEO) 3000 stimuli reduced [integral]MEPCs by 60 %, because with acetylcholinesterase (AChE) inhibited, [integral]MEPC size is more sensitive to changes in acetylcholine (ACh) content. Neostigmine 38-49 acetylcholinesterase (Cartwright blood group) Homo sapiens 137-141 11313435-5 2001 When the solution contained 10 microM neostigmine (NEO) 3000 stimuli reduced [integral]MEPCs by 60 %, because with acetylcholinesterase (AChE) inhibited, [integral]MEPC size is more sensitive to changes in acetylcholine (ACh) content. Neostigmine 51-54 acetylcholinesterase (Cartwright blood group) Homo sapiens 115-135 11313435-5 2001 When the solution contained 10 microM neostigmine (NEO) 3000 stimuli reduced [integral]MEPCs by 60 %, because with acetylcholinesterase (AChE) inhibited, [integral]MEPC size is more sensitive to changes in acetylcholine (ACh) content. Neostigmine 51-54 acetylcholinesterase (Cartwright blood group) Homo sapiens 137-141 11181580-5 2001 One probe was perfused with the AChE inhibitor neostigmine (10 microM); the adjacent membrane was perfused with the vehicle (Ringer solution). Neostigmine 47-58 acetylcholinesterase (Cartwright blood group) Homo sapiens 32-36 11031092-4 2000 In MG patients, the open-loop gains of OKN increased significantly after the intramuscular injection of an acetylcholinesterase inhibitor, neostigmine, while the closed-loop OKN gains were not significantly changed. Neostigmine 139-150 acetylcholinesterase (Cartwright blood group) Homo sapiens 107-127 10499750-1 1999 BACKGROUND AND OBJECTIVES: The acetylcholinesterase inhibitor neostigmine has shown peripherally mediated analgesic action in recent preclinical and clinical studies. Neostigmine 62-73 acetylcholinesterase (Cartwright blood group) Homo sapiens 31-51 10585525-4 1999 Microdialysis was performed with a Ringer containing low concentrations (0.01 microM) of the acetylcholinesterase inhibitor, neostigmine. Neostigmine 125-136 acetylcholinesterase (Cartwright blood group) Homo sapiens 93-113 9279814-9 1997 The desensitization of ACh receptors potentiated by proadifen, prevented completely the 6- to 8-fold prolongation of EPC which was induced by neostigmine inhibition of synaptic AChE. Neostigmine 142-153 acetylcholinesterase (Cartwright blood group) Homo sapiens 177-181 8264551-3 1993 Present results show that AE-2 decreases the rate of inhibition of FBS AChE by the positively charged organophosphate amiton-p-toluene sulfonate and the positively charged carbamates pyridostigmine and neostigmine but accelerates inhibition of FBS AChE by the neutral organophosphates paraoxon and diisopropylfluorophosphate. Neostigmine 202-213 acetylcholinesterase (Cartwright blood group) Homo sapiens 71-75 1547059-0 1992 Effects of neostigmine and edrophonium on human erythrocyte acetylcholinesterase activity. Neostigmine 11-22 acetylcholinesterase (Cartwright blood group) Homo sapiens 60-80 1547059-2 1992 Erythrocyte AChE activities decreased to 11.3 (SD 1.2)% and 11.4 (0.8)% of baseline values (P less than 0.001) within 2 min, then recovered slowly and were 43.2 (6.2)% and 27.9 (2.9)% (P less than 0.001) 60 min after administration of neostigmine 0.036 mg kg-1 and 0.071 mg kg-1, respectively. Neostigmine 235-246 acetylcholinesterase (Cartwright blood group) Homo sapiens 12-16 9729629-11 1998 Acetylcholinesterase (AChE) may not be involved in SP degradation since Ca2+ responses evoked by SP were unchanged in the presence of the cholinesterase inhibitor neostigmine. Neostigmine 163-174 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 9489729-2 1998 Systemic administration of d-amphetamine (2 or 10 mg/kg) increased the striatal output of ACh when the AChE inhibitor neostigmine (0.1 microM) was present in the perfusion fluid. Neostigmine 118-129 acetylcholinesterase (Cartwright blood group) Homo sapiens 103-107 9477052-11 1998 CONCLUSIONS: Intra-articular injection of the acetylcholinesterase inhibitor neostigmine produced a moderate but significant analgesic effect. Neostigmine 77-88 acetylcholinesterase (Cartwright blood group) Homo sapiens 46-66 8987799-5 1997 A second series of experiments demonstrated that mPRF microinjection of NLA significantly reduced the amount of REM sleep and the REM sleep-like state caused by mPRF injection of the acetylcholinesterase inhibitor neostigmine. Neostigmine 214-225 acetylcholinesterase (Cartwright blood group) Homo sapiens 183-203